Oncology Institute Ownership
| TOI Stock | USD 1.00 0.01 0.99% |
Shares in Circulation | First Issued 2018-12-31 | Previous Quarter 74.7 M | Current Value 75.5 M | Avarage Shares Outstanding 65.3 M | Quarterly Volatility 20.1 M |
Oncology |
Oncology Stock Ownership Analysis
About 20.0% of the company outstanding shares are owned by corporate insiders. The book value of Oncology Institute was at this time reported as 0.77. The company has Price/Earnings (P/E) ratio of 190.67. Oncology Institute recorded a loss per share of 0.77. The entity had not issued any dividends in recent years. The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California. Oncology Institute operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 658 people. To find out more about Oncology Institute contact Bradford Hively at 562 735 3226 or learn more at https://theoncologyinstitute.com.Besides selling stocks to institutional investors, Oncology Institute also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Oncology Institute's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Oncology Institute's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Oncology Institute Quarterly Liabilities And Stockholders Equity |
|
About 20.0% of Oncology Institute are currently held by insiders. Unlike Oncology Institute's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Oncology Institute's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Oncology Institute's insider trades
Oncology Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oncology Institute is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oncology Institute backward and forwards among themselves. Oncology Institute's institutional investor refers to the entity that pools money to purchase Oncology Institute's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Freegulliver, Llc | 2024-09-30 | 188.2 K | Renaissance Technologies Corp | 2024-09-30 | 170 K | Bank Of New York Mellon Corp | 2024-09-30 | 125.1 K | State Street Corp | 2024-09-30 | 101.3 K | Saba Capital Management, Lp | 2024-09-30 | 94.3 K | Citadel Advisors Llc | 2024-09-30 | 91.3 K | Lee Financial Corp | 2024-09-30 | 81.4 K | Hightower Advisors, Llc | 2024-09-30 | 81.4 K | Fielder Capital Group Llc | 2024-09-30 | 70.2 K | Fmr Inc | 2024-09-30 | 4.7 M | Deerfield Management Co | 2024-09-30 | 3.4 M |
Oncology Institute Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncology Institute insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncology Institute's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oncology Institute insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oncology Institute Outstanding Bonds
Oncology Institute issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oncology Institute uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oncology bonds can be classified according to their maturity, which is the date when Oncology Institute has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US68233JBV52 Corp BondUS68233JBV52 | View | |
| US68233JBU79 Corp BondUS68233JBU79 | View | |
| US68233JBR41 Corp BondUS68233JBR41 | View | |
| US68233JBP84 Corp BondUS68233JBP84 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBG85 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBH68 | View |
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth 0.229 | Return On Assets | Return On Equity |
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.